Skip to main content

Table 2 Characteristics of patients without diabetes according to concomitant events.

From: Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes

 

1. No-diabetes w/o event

2. No-diabetes with event

NHIS

NHIS + Eze

HIS

HIS + Eze

p value*

NHIS

NHIS + Eze

HIS

HIS + Eze

p value*

Nr. patients

16,131 (85)

1305 (7)

1492 (8)

123 (1)

 

3946 (47)

738 (9)

3265 (39)

374 (5)

 

Adherent

12,586 (78)

1091 (84)

1213 (81)

112 (91)

< 0.001

3186 (81)

660 (89)

2767 (85)

356 (95)

< 0.001

Total-chol (mg/dl)a

180.3 (37)

178.5 (43)

168.7 (43)

170.1 (46)

< 0.001

152.6 (39)

150.2 (36)

139.1 (33)

136.6 (33)

< 0.001

LDL-chol (mg/dl)a

103.8 (31)

100.8 (36)

95.6 (36)

100 (42)

< 0.001

84.5 (31)

79.5 (28)

75.4 (27)

72.7 (26)

< 0.001

HDL-chol (mg/dl)a

56.2 (16)

55.6 (15)

52.7 (16)

52.5 (14)

< 0.001

49 (16)

50.6 (15)

46.5 (14)

47.2 (13)

< 0.001

Triglycerides (mg/dl)a

97.6 (58)

102.9 (65)

97.2 (66)

85.1 (47)

0.001

86.4 (59)

92.4 (65)

78.7 (54)

74 (48)

< 0.001

NON-HDL-chol (mg/dl)a

124.1 (34)

122.8 (42)

116 (40)

117.6 (45)

< 0.001

103.6 (35)

99.6 (33)

92.6 (30)

89.4 (31)

< 0.001

GFR (ml/min/1.73 m2)a

91.8 (26)

89.6 (25)

95.2 (31)

93.4 (44)

< 0.001

80.4 (34)

80.3 (30)

89.6 (30)

92.3 (23)

< 0.001

HbA1c (mmol/mol)a

41 (8)

40.8 (6)

41.3 (7)

40.7 (6)

N.S

40 (7)

39.7 (5)

39.6 (6)

40.6 (8)

N.S

CHD

     

1672 (42)

398 (54)

1197 (37)

215 (58)

< 0.001

Cerebrovascular disease

     

1565 (40)

171 (23)

1307 (40)

44 (12)

< 0.001

PAD

     

4 (0)

N.I

N.I

0 (0)

N.S

ACEi/ARB

9001 (56)

710 (54)

906 (61)

77 (63)

0.001

2608 (66)

520 (71)

2269 (70)

278 (74)

< 0.001

Beta blockers

4178 (26)

359 (28)

539 (36)

51 (42)

< 0.001

2041 (52)

491 (67)

1914 (59)

277 (74)

< 0.001

CCB

3183 (20)

248 (19)

296 (20)

16 (13)

N.S

1096 (28)

183 (25)

782 (24)

72 (19)

< 0.001

Fibrates

83 (1)

7 (1)

12 (1)

N.I

N.S

16 (0)

7 (1)

9 (0)

N.I

N.S

  1. Opinion 05/2014 on “Anonymisation Techniques” drafted by the “European Commission Article 29 Working Party”, the analyses involving less than three patients were not reported, as potentially reconductable to single individuals. Therefore, results referred to ≤ 3 patients were reported as NI (not issuable)
  2. CHD coronary heart disease, PAD peripheral artery disease, ACEi angiotensin converting-enzyme inhibitors, ARBs angiotensin II receptor blocker, CCB calcium channel blockers
  3. *ANOVA P value for differences between groups (i.e., if < 0.05 not all group are equivalent)
  4. aAnalyses performed on patients with at least one detection before index
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840